RYTM – Rhythm Pharmaceuticals Inc.
RYTM — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
10.27
Margin Of Safety %
Put/Call OI Ratio
0.1
EPS Next Q Diff
-1.24
EPS Last/This Y
-0.04
EPS This/Next Y
2.78
Price
86.66
Target Price
137.67
Analyst Recom
1.12
Performance Q
-14.92
Upside
-225.6%
Beta
2.2
Ticker: RYTM
16 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | RYTM | 93.06 | 0.52 | 0.29 | 1787 |
| 2026-03-10 | RYTM | 93.07 | 0.51 | 0.00 | 1801 |
| 2026-03-11 | RYTM | 89.98 | 0.49 | 0.08 | 1860 |
| 2026-03-12 | RYTM | 91.29 | 0.43 | 0.16 | 2089 |
| 2026-03-13 | RYTM | 91.15 | 0.43 | 0.16 | 2089 |
| 2026-03-17 | RYTM | 87.77 | 0.29 | 1.51 | 2826 |
| 2026-03-18 | RYTM | 85.9 | 0.48 | 0.26 | 3546 |
| 2026-03-20 | RYTM | 87.46 | 0.38 | 0.24 | 4766 |
| 2026-03-25 | RYTM | 84.52 | 0.14 | 0.04 | 3270 |
| 2026-03-26 | RYTM | 81.85 | 0.14 | 0.17 | 3296 |
| 2026-03-27 | RYTM | 75.93 | 0.13 | 0.06 | 3370 |
| 2026-03-30 | RYTM | 77.31 | 0.12 | 0.02 | 3799 |
| 2026-03-31 | RYTM | 86.21 | 0.12 | 0.00 | 3764 |
| 2026-04-01 | RYTM | 88.23 | 0.10 | 0.01 | 4363 |
| 2026-04-06 | RYTM | 86.9 | 0.10 | 0.67 | 4395 |
| 2026-04-07 | RYTM | 86.71 | 0.10 | 0.05 | 4408 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
16 items
«
‹
Current Page1 of 1
›
»
20 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | RYTM | 93.03 | -1.2 | - | -2.99 |
| 2026-03-10 | RYTM | 93.03 | -1.2 | - | -2.99 |
| 2026-03-11 | RYTM | 90.01 | -1.2 | - | -2.99 |
| 2026-03-12 | RYTM | 91.18 | -1.2 | - | -2.99 |
| 2026-03-13 | RYTM | 87.37 | -1.2 | - | -2.99 |
| 2026-03-17 | RYTM | 87.72 | -1.2 | - | -2.99 |
| 2026-03-18 | RYTM | 85.89 | -1.2 | - | -2.99 |
| 2026-03-19 | RYTM | 90.39 | -1.2 | - | -2.99 |
| 2026-03-20 | RYTM | 87.44 | -3.4 | - | -3.09 |
| 2026-03-23 | RYTM | 84.59 | -3.4 | - | -3.09 |
| 2026-03-24 | RYTM | 82.59 | -3.4 | - | -3.07 |
| 2026-03-25 | RYTM | 84.60 | -3.4 | - | -3.07 |
| 2026-03-26 | RYTM | 81.84 | -3.4 | - | -3.07 |
| 2026-03-27 | RYTM | 75.84 | -3.4 | - | -3.07 |
| 2026-03-30 | RYTM | 77.23 | -3.4 | - | -3.07 |
| 2026-03-31 | RYTM | 87.03 | -3.4 | - | -3.07 |
| 2026-04-01 | RYTM | 88.20 | -3.4 | - | -3.07 |
| 2026-04-02 | RYTM | 86.31 | -3.4 | - | -3.07 |
| 2026-04-06 | RYTM | 86.97 | -7.3 | - | -3.15 |
| 2026-04-07 | RYTM | 86.66 | -7.3 | - | -3.15 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
20 items
«
‹
Current Page1 of 1
›
»
19 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | RYTM | -1.79 | 1.15 | 9.46 |
| 2026-03-10 | RYTM | -1.79 | 1.15 | 9.46 |
| 2026-03-11 | RYTM | -1.79 | 1.15 | 9.93 |
| 2026-03-12 | RYTM | -1.79 | 1.15 | 9.93 |
| 2026-03-13 | RYTM | -1.79 | 1.15 | 9.93 |
| 2026-03-18 | RYTM | -1.79 | 1.15 | 9.93 |
| 2026-03-19 | RYTM | -1.79 | 1.15 | 9.93 |
| 2026-03-20 | RYTM | -1.79 | 1.15 | 9.93 |
| 2026-03-23 | RYTM | -1.79 | 1.15 | 9.93 |
| 2026-03-24 | RYTM | -1.79 | 1.15 | 9.93 |
| 2026-03-25 | RYTM | -1.79 | 1.15 | 10.27 |
| 2026-03-26 | RYTM | -1.79 | 1.15 | 10.27 |
| 2026-03-27 | RYTM | -1.79 | 1.15 | 10.27 |
| 2026-03-30 | RYTM | -1.79 | 1.15 | 10.27 |
| 2026-03-31 | RYTM | -1.79 | 1.15 | 10.27 |
| 2026-04-01 | RYTM | -1.79 | 1.15 | 10.27 |
| 2026-04-02 | RYTM | -1.79 | 1.15 | 10.27 |
| 2026-04-06 | RYTM | -1.79 | 1.15 | 10.27 |
| 2026-04-07 | RYTM | -1.79 | 1.15 | 10.27 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
19 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
0.43
Avg. EPS Est. Current Quarter
-0.84
Avg. EPS Est. Next Quarter
-0.81
Insider Transactions
-1.79
Institutional Transactions
1.15
Beta
2.2
Average Sales Estimate Current Quarter
55
Average Sales Estimate Next Quarter
66
Fair Value
Quality Score
44
Growth Score
54
Sentiment Score
90
Actual DrawDown %
29.1
Max Drawdown 5-Year %
-86.2
Target Price
137.67
P/E
Forward P/E
PEG
P/S
31.18
P/B
41.88
P/Free Cash Flow
EPS
-3.11
Average EPS Est. Cur. Y
-3.15
EPS Next Y. (Est.)
-0.36
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-106.41
Relative Volume
0.9
Return on Equity vs Sector %
-102.2
Return on Equity vs Industry %
-85.7
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.22
EBIT Estimation
◆
RYTM
Healthcare
$86.66
📉
N/A
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
8/20
Pullback
19/25
Volume
4/15
Valuation
10/20
TP/AR
4/10
Options
6/10
RSI
47.4
Range 1M
48.1%
Sup Dist
1.1%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
3/25
Growth
17/30
Estimates
4/20
Inst/Vol
5/15
Options
10/10
EPS Yr
1.2%
EPS NY
83.1%
52W%
51%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+58.9% upside
Quality
6/30
Valuation
10/30
Growth
13/25
Stability
6/10
LT Trend
3/5
Upside
+58.9%
Quality
44
Click a card to see score breakdown
Full Analysis →
Sector: Healthcare
Industry: Biotechnology
Employees: 414
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
RYTM
Latest News
—
Caricamento notizie per RYTM…
stock quote shares RYTM – Rhythm Pharmaceuticals Inc. Stock Price stock today
news today RYTM – Rhythm Pharmaceuticals Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RYTM – Rhythm Pharmaceuticals Inc. yahoo finance google finance
stock history RYTM – Rhythm Pharmaceuticals Inc. invest stock market
stock prices RYTM premarket after hours
ticker RYTM fair value insiders trading